NASDAQ:IDRA - Idera Pharmaceuticals Stock Price, Price Target & More

$1.77 +0.01 (+0.57 %)
(As of 04/19/2018 07:54 AM ET)
Previous Close$1.76
Today's Range$1.76 - $1.80
52-Week Range$1.32 - $2.87
Volume385,600 shs
Average Volume1.71 million shs
Market Capitalization$380.17 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35

About Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IDRA
CUSIPN/A
Phone617-679-5500

Debt

Debt-to-Equity RatioN/A
Current Ratio11.55%
Quick Ratio11.55%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$900,000.00
Price / Sales424.82
Cash FlowN/A
Price / CashN/A
Book Value$0.55 per share
Price / Book3.22

Profitability

EPS (Most Recent Fiscal Year)($0.42)
Net Income$-65,980,000.00
Net Margins-7,315.30%
Return on Equity-78.83%
Return on Assets-71.32%

Miscellaneous

Employees62
Outstanding Shares216,010,000

How to Become a New Pot Stock Millionaire

Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) released its earnings results on Wednesday, March, 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.00. The biotechnology company earned $0.17 million during the quarter, compared to analysts' expectations of $0.30 million. Idera Pharmaceuticals had a negative net margin of 7,315.30% and a negative return on equity of 78.83%. View Idera Pharmaceuticals' Earnings History.

What price target have analysts set for IDRA?

3 analysts have issued 1-year price targets for Idera Pharmaceuticals' shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Idera Pharmaceuticals' share price to reach $4.3333 in the next year. View Analyst Ratings for Idera Pharmaceuticals.

Are investors shorting Idera Pharmaceuticals?

Idera Pharmaceuticals saw a drop in short interest in March. As of March 15th, there was short interest totalling 3,045,993 shares, a drop of 27.7% from the February 28th total of 4,212,511 shares. Based on an average daily trading volume, of 1,277,336 shares, the short-interest ratio is presently 2.4 days. Currently, 1.8% of the company's stock are short sold.

Who are some of Idera Pharmaceuticals' key competitors?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Milano, CEO, Pres & Director (Age 54)
  • Mr. Louis J. Arcudi III, Principal Accounting Officer, Sr. VP of Operations, CFO, Treasurer & Assistant Sec. (Age 57)
  • Mr. Mark J. Casey, Sr. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 55)
  • Mr. Julian Charles Baker, Exec. Director of Market Devel. & Director (Age 51)

Has Idera Pharmaceuticals been receiving favorable news coverage?

Media headlines about IDRA stock have trended somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Idera Pharmaceuticals earned a coverage optimism score of 0.17 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.80 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $1.77.

How big of a company is Idera Pharmaceuticals?

Idera Pharmaceuticals has a market capitalization of $380.17 million and generates $900,000.00 in revenue each year. The biotechnology company earns $-65,980,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Idera Pharmaceuticals employs 62 workers across the globe.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 167 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-679-5500 or via email at [email protected]


MarketBeat Community Rating for Idera Pharmaceuticals (IDRA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  336
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Idera Pharmaceuticals (NASDAQ:IDRA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Idera Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.3333, suggesting that the stock has a possible upside of 144.82%. The high price target for IDRA is $5.00 and the low price target for IDRA is $4.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.3333$5.40$5.40$5.75
Price Target Upside: 144.82% upside167.33% upside172.73% upside179.81% upside

Idera Pharmaceuticals (NASDAQ:IDRA) Consensus Price Target History

Price Target History for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ:IDRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018HC WainwrightSet Price TargetBuy$4.00MediumView Rating Details
9/12/2017Piper JaffrayReiterated RatingBuy$4.00LowView Rating Details
4/24/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$5.00MediumView Rating Details
4/11/2017WedbushReiterated RatingOutperform$6.00LowView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$8.00HighView Rating Details
11/29/2016CowenReiterated RatingOutperformN/AView Rating Details
10/7/2016S&P Equity ResearchBoost Price Target$1.86 -> $2.10N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Idera Pharmaceuticals (NASDAQ:IDRA) Earnings History and Estimates Chart

Earnings by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ:IDRA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.10)($0.10)($0.10)

Idera Pharmaceuticals (NASDAQ IDRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018Q4 2017($0.0820)($0.08)$0.30 million$0.17 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.1220)($0.10)$0.20 million$0.16 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.1070)($0.14)$0.20 million$0.19 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.0970)($0.10)$0.20 million$0.38 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.11)$0.01$0.32 million$15.28 millionViewN/AView Earnings Details
10/28/2016Q3($0.1130)($0.10)$0.30 million$0.32 millionViewN/AView Earnings Details
8/2/2016Q216($0.11)($0.11)$0.30 million$0.30 millionViewN/AView Earnings Details
5/9/2016Q1($0.11)($0.11)$0.20 million$0.29 millionViewListenView Earnings Details
3/10/2016Q4($0.11)($0.10)$0.03 million$0.19 millionViewN/AView Earnings Details
11/6/2015Q315($0.11)($0.10)$0.02 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.11)$0.01 millionViewN/AView Earnings Details
5/11/2015Q1($0.11)($0.12)$0.03 million$0.03 millionViewN/AView Earnings Details
3/12/2015Q414($0.11)($0.14)$0.03 millionViewN/AView Earnings Details
11/7/2014Q314($0.11)($0.11)$0.03 millionViewListenView Earnings Details
8/12/2014Q214($0.09)($0.10)$0.04 millionViewListenView Earnings Details
5/13/2014Q114($0.08)($0.12)ViewListenView Earnings Details
3/13/2014Q4($0.08)($0.10)ViewListenView Earnings Details
11/14/2013Q3($0.11)($0.11)$0.03 million$0.0070 millionViewListenView Earnings Details
8/15/2013Q213($0.12)($0.15)$0.03 millionViewN/AView Earnings Details
5/15/2013Q113($0.19)($0.15)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.24)ViewN/AView Earnings Details
11/12/2012Q312($0.17)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.15)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.26)($0.22)ViewN/AView Earnings Details
3/14/2012Q4 2011($0.21)($0.40)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.20)($0.20)ViewN/AView Earnings Details
8/5/2011Q2 2011($0.25)($0.23)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.20)($0.25)ViewN/AView Earnings Details
3/10/2011Q4 2010($0.24)($0.22)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.06)($0.18)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.02($0.23)ViewN/AView Earnings Details
5/4/2010Q1 2010($0.01)($0.08)ViewN/AView Earnings Details
3/10/2010Q4 2009$0.17ViewN/AView Earnings Details
8/4/2009Q2 2009($0.01)$0.16ViewN/AView Earnings Details
5/6/2009Q1 2009$0.01($0.01)ViewN/AView Earnings Details
3/11/2009Q4 2008$0.01$0.02ViewN/AView Earnings Details
11/6/2008Q3 2008($0.03)$0.08ViewN/AView Earnings Details
8/1/2008Q2 2008($0.09)$0.05ViewN/AView Earnings Details
5/12/2008Q1 2008$0.39($0.10)ViewN/AView Earnings Details
3/4/2008Q4 2007($0.18)($0.21)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Idera Pharmaceuticals (NASDAQ:IDRA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Idera Pharmaceuticals (NASDAQ IDRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.42%
Institutional Ownership Percentage: 33.14%
Insider Trading History for Idera Pharmaceuticals (NASDAQ:IDRA)
Institutional Ownership by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ IDRA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2018Invest Corp PillarMajor ShareholderSell200,000$2.40$480,000.00View SEC Filing  
12/15/2017Invest Corp PillarMajor ShareholderSell2,300,000$1.96$4,508,000.00View SEC Filing  
12/13/2017Invest Corp PillarMajor ShareholderSell1,100,000$1.93$2,123,000.00View SEC Filing  
10/26/2017Bros. Advisors Lp BakerDirectorBuy8,000,000$1.50$12,000,000.00View SEC Filing  
5/1/2017Invest Corp PillarDirectorSell450,815$2.26$1,018,841.90View SEC Filing  
4/25/2017Invest Corp PillarDirectorSell1,328,422$2.29$3,042,086.38View SEC Filing  
4/24/2017Invest Corp PillarDirectorSell437,829$2.29$1,002,628.41View SEC Filing  
10/7/2016Julian BakerDirectorBuy3,250,000$2.00$6,500,000.00View SEC Filing  
10/3/2016Maxine GowenDirectorBuy4,102$2.56$10,501.1210,543View SEC Filing  
5/13/2016James A GeraghtyDirectorBuy10,000$1.34$13,400.00425,649View SEC Filing  
5/12/2016Mark J CaseyVPBuy34,450$1.44$49,608.0034,450View SEC Filing  
3/15/2016Vincent MilanoCEOBuy40,000$1.97$78,800.00246,527View SEC Filing  
2/13/2015Julian BakerDirectorBuy5,333,333$3.75$19,999,998.75View SEC Filing  
12/16/2014Youssef El ZeinDirectorSell100,000$3.68$368,000.00View SEC Filing  
12/12/2014Vincent MilanoCEOBuy200,000$4.00$800,000.00View SEC Filing  
5/27/2014James A GeraghtyDirectorBuy10,000$2.65$26,500.00View SEC Filing  
12/6/2013James A GeraghtyDirectorBuy40,000$2.72$108,800.00View SEC Filing  
9/16/2013James A GeraghtyDirectorBuy60,000$1.90$114,000.00View SEC Filing  
8/19/2013James A GeraghtyDirectorBuy300,000$1.75$525,000.00View SEC Filing  
5/7/2013C Keith HartleyDirectorBuy90,000$0.49$44,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Idera Pharmaceuticals (NASDAQ IDRA) News Headlines

Source:
DateHeadline
Idera Pharmaceuticals (IDRA) Lifted to "Hold" at ValuEngineIdera Pharmaceuticals (IDRA) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM
Active-Investors: Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners FoundationActive-Investors: Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation
www.finanznachrichten.de - April 18 at 9:36 AM
Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125
www.nasdaq.com - April 17 at 9:22 AM
Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual MeetingIdera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting
finance.yahoo.com - April 17 at 9:22 AM
Pillar Partners to provide funding for up to three Investigator Initiated Clinical TrialsPillar Partners to provide funding for up to three Investigator Initiated Clinical Trials
globenewswire.com - April 16 at 9:35 AM
Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory MelanomaIdera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma
finance.yahoo.com - April 16 at 9:35 AM
Idera Pharmaceuticals (IDRA) Rating Increased to Hold at Zacks Investment ResearchIdera Pharmaceuticals (IDRA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM
[$$] Activist Starboard Value Looks Into Forest City Realty[$$] Activist Starboard Value Looks Into Forest City Realty
finance.yahoo.com - April 6 at 4:46 PM
Idera Pharmaceuticals (IDRA) Cut to Strong Sell at ValuEngineIdera Pharmaceuticals (IDRA) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 6 at 11:38 AM
Why another BioCryst shareholder plans to vote against Idera mergerWhy another BioCryst shareholder plans to vote against Idera merger
finance.yahoo.com - April 3 at 4:40 PM
RA Capital Management Opposes BioCryst Pharmaceuticals Proposed Merger with Idera PharmaceuticalsRA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals
finance.yahoo.com - April 2 at 4:43 PM
Idera Pharmaceuticals, Inc. (IDRA) Given Average Recommendation of "Hold" by BrokeragesIdera Pharmaceuticals, Inc. (IDRA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 1 at 3:26 AM
Idera Pharmaceuticals (IDRA) Now Covered by HC WainwrightIdera Pharmaceuticals (IDRA) Now Covered by HC Wainwright
www.americanbankingnews.com - March 31 at 8:16 PM
Idera Pharmaceuticals Inc (IDRA) Short Interest UpdateIdera Pharmaceuticals Inc (IDRA) Short Interest Update
www.americanbankingnews.com - March 30 at 3:38 AM
Idera Pharmaceuticals (IDRA) Downgraded by BidaskClubIdera Pharmaceuticals (IDRA) Downgraded by BidaskClub
www.americanbankingnews.com - March 29 at 11:28 AM
Idera Pharmaceuticals (IDRA) Raised to "Strong-Buy" at BidaskClubIdera Pharmaceuticals (IDRA) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 28 at 12:34 AM
Idera Pharmaceuticals (IDRA) Downgraded by Zacks Investment Research to HoldIdera Pharmaceuticals (IDRA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 27 at 10:56 PM
Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals ... - GlobeNewswire (press release)Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals ... - GlobeNewswire (press release)
globenewswire.com - March 24 at 8:19 AM
Idera Pharmaceuticals (IDRA) Lifted to "Sell" at ValuEngineIdera Pharmaceuticals (IDRA) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - March 23 at 10:46 PM
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare ConferenceBioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 22 at 4:52 PM
BioCryst launches trial of drug at center of planned merger - Triangle Business JournalBioCryst launches trial of drug at center of planned merger - Triangle Business Journal
www.bizjournals.com - March 17 at 4:49 PM
Head-To-Head Survey: Idera Pharmaceuticals (IDRA) & Immutep (IMMP)Head-To-Head Survey: Idera Pharmaceuticals (IDRA) & Immutep (IMMP)
www.americanbankingnews.com - March 17 at 1:02 AM
Idera Pharmaceuticals (IDRA) Upgraded at BidaskClubIdera Pharmaceuticals (IDRA) Upgraded at BidaskClub
www.americanbankingnews.com - March 10 at 4:33 PM
Idera Pharmaceuticals (IDRA) Downgraded by Zacks Investment Research to "Sell"Idera Pharmaceuticals (IDRA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 10 at 12:30 AM
HC Wainwright Reiterates "$4.00" Price Target for Idera Pharmaceuticals (IDRA)HC Wainwright Reiterates "$4.00" Price Target for Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - March 9 at 7:31 PM
Idera Pharmaceuticals (IDRA) Posts Quarterly  Earnings ResultsIdera Pharmaceuticals (IDRA) Posts Quarterly Earnings Results
www.americanbankingnews.com - March 8 at 9:58 AM
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate UpdateIdera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 7 at 9:49 AM
Idera reports 4Q lossIdera reports 4Q loss
finance.yahoo.com - March 7 at 9:49 AM
Idera Pharmaceuticals Inc (IDRA) Given Consensus Rating of "Buy" by AnalystsIdera Pharmaceuticals Inc (IDRA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 7 at 3:44 AM
Idera Pharmaceuticals (IDRA) Downgraded to "Strong Sell" at ValuEngineIdera Pharmaceuticals (IDRA) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 4 at 4:28 PM
Idera Pharmaceuticals Inc (IDRA) Position Reduced by Broadfin Capital LLCIdera Pharmaceuticals Inc (IDRA) Position Reduced by Broadfin Capital LLC
www.americanbankingnews.com - March 3 at 4:53 AM
BioCryst, Idera outline specifics on merger valueBioCryst, Idera outline specifics on merger value
finance.yahoo.com - February 26 at 9:37 AM
Idera Pharmaceuticals (IDRA) versus Oramed Pharmaceuticals (ORMP) Head-To-Head ContrastIdera Pharmaceuticals (IDRA) versus Oramed Pharmaceuticals (ORMP) Head-To-Head Contrast
www.americanbankingnews.com - February 22 at 1:50 PM
Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.
finance.yahoo.com - February 16 at 4:42 PM
Idera Pharmaceuticals Inc (IDRA) Receives Consensus Recommendation of "Buy" from AnalystsIdera Pharmaceuticals Inc (IDRA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 10 at 3:42 AM
RM LAW Announces Investigation of Idera Pharmaceuticals, Inc. - PR Newswire (press release)RM LAW Announces Investigation of Idera Pharmaceuticals, Inc. - PR Newswire (press release)
www.prnewswire.com - January 30 at 3:24 PM
RM LAW Announces Investigation of Idera Pharmaceuticals, Inc.RM LAW Announces Investigation of Idera Pharmaceuticals, Inc.
finance.yahoo.com - January 30 at 3:24 PM
Idera Pharmaceuticals (IDRA) Stock Rating Lowered by BidaskClubIdera Pharmaceuticals (IDRA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 28 at 8:54 AM
BioCryst Pharma and Idera Pharma tie the knot - Seeking Alpha - Seeking AlphaBioCryst Pharma and Idera Pharma tie the knot - Seeking Alpha - Seeking Alpha
seekingalpha.com - January 23 at 3:29 PM
BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) Announce MergerBioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) Announce Merger
www.streetinsider.com - January 23 at 11:52 AM
BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No LoveBioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love
finance.yahoo.com - January 23 at 11:52 AM
Cambridges Idera plans eventual move out of state after merger with BioCrystCambridge's Idera plans eventual move out of state after merger with BioCryst
finance.yahoo.com - January 23 at 11:52 AM
BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares FallBioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall
finance.yahoo.com - January 23 at 11:52 AM
Idera Pharmaceuticals (IDRA) Given a $4.00 Price Target at HC WainwrightIdera Pharmaceuticals (IDRA) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - January 23 at 8:08 AM
Bragar Eagel & Squire, PC is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of ... - Business Wire (press release)Bragar Eagel & Squire, PC is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of ... - Business Wire (press release)
www.businesswire.com - January 22 at 3:30 PM
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More ... - GlobeNewswire (press release)BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More ... - GlobeNewswire (press release)
globenewswire.com - January 22 at 3:30 PM
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare DiseasesBioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
finance.yahoo.com - January 22 at 3:30 PM
BioCryst and Idera to merge into rare disease companyBioCryst and Idera to merge into rare disease company
finance.yahoo.com - January 22 at 3:30 PM
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - January 22 at 3:30 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Idera Pharmaceuticals, Inc. to BioCryst Pharmaceuticals, Inc. is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Idera Pharmaceuticals, Inc. to BioCryst Pharmaceuticals, Inc. is Fair to Shareholders
finance.yahoo.com - January 22 at 3:30 PM

SEC Filings

Idera Pharmaceuticals (NASDAQ:IDRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Idera Pharmaceuticals (NASDAQ:IDRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Idera Pharmaceuticals (NASDAQ IDRA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.